- Generics sales rose a third to $400m in the six months ending June
- The generics unit launched four products in the first half
A strong first half for Hikma Pharmaceuticals (HIK) has prompted the FTSE 100 company to raise its full-year guidance, even as it lapped a particularly strong start to 2021.